• KinATLAS
  • TranscriptoNET
  • PhosphoNET
  • OncoNET
  • KinaseNET
  • DrugKiNET
  • DrugProNET
  • KiNET-AM
  • Kinetica Online

Updated November 2019

Home | Kinexus | Contact | Credits

Nomenclature

Short Name:
CCK4
Full Name:
Tyrosine-protein kinase-like 7
Alias:
  • Colon carcinoma kinase-4
  • CCK-4
  • PTK7

Classification

Type:
Protein-tyrosine kinase
Group:
TK
Family:
CCK4
SubFamily:
NA
 
 

Specific Links

Entrez-Gene Entry: 5754
Entrez-Protein Entry: NP_002812
GeneCards Entry: CCK4
KinBASE Entry: CCK4
OMIM Entry: 601890
Pfam Entry: Q13308
PhosphoNET Entry: Q13308
Phosphosite Plus Entry: 1897
ScanSite Entry: Q13308
Source Entry: PTK7
UCSD-Nature Entry: A001943
UniProt Entry: Q13308

General Links

ClustalW2
GPS-Cuckoo
Human Protein Atlas
Kinase.com
Kinase Research
Kinasource
Kinomer
Netphorest
NetworKIN
Phosida
PhosphoElm
Protein Blast
ScanSite
String

Structure

Mol. Mass (Da):
118392
# Amino Acids:
1070
# mRNA Isoforms:
6
mRNA Isoforms:
119,197 Da (1078 AA; Q13308-6); 118,392 Da (1070 AA; Q13308); 113,805 Da (1030 AA; Q13308-2); 112,261 Da (1014 AA; Q13308-4); 103,581 Da (940 AA; Q13308-3); 89,764 Da (816 AA; Q13308-5)
4D Structure:
NA
1D Structure:
Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence
 
Subfamily Alignment
subfamily domain
 
Domain Distribution:
Start End Domain
1 30 signal_peptide
31 120 IGc2
128 218 IGc2
225 317 IGc2
309 407 IGc2
412 497 IGc2
503 586 IGc2
578 680 IGc2
704 726 TMD
796 1061 TyrKc
796 1063 Pkinase
 

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET
N-GlcNAcylated:
N116, N175, N184, N214, N268, N283, N405, N463, N567, N646.
Serine phosphorylated:

S39, S40, S285, S542, S543, S784, S786.
Threonine phosphorylated:

T279, T561, T785.
Tyrosine phosphorylated:

Y872, Y877, Y960+.
Ubiquitinated:
K132, K181, K636, K804, K835, K898, K1069.
 

Distribution

Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:
  • adipose
    42

    896

    28

    1333

  • adrenal
    2

    37

    10

    32

  • bladder
    5

    103

    20

    192

  • brain
    67

    1419

    93

    3424

  • breast
    34

    723

    21

    677

  • cervix
    6

    133

    53

    213

  • colon
    9

    184

    29

    427

  • heart
    100

    2116

    46

    4262

  • intestine
    13

    266

    10

    234

  • kidney
    5

    102

    61

    126

  • liver
    3

    67

    32

    138

  • lung
    26

    550

    130

    593

  • lymphnode
    4

    85

    31

    153

  • ovary
    10

    207

    9

    123

  • pancreas
    2

    39

    9

    19

  • pituitary
    1

    20

    13

    16

  • prostate
    3

    67

    122

    120

  • salivarygland
    13

    281

    26

    1050

  • skeletalmuscle"
    1

    22

    62

    22

  • skin
    27

    566

    79

    565

  • spinalcord
    3

    63

    29

    100

  • spleen
    5

    106

    31

    124

  • stomach
    3

    74

    29

    101

  • testis
    2

    50

    27

    49

  • thymus
    7

    140

    29

    137

  • thyroid
    37

    781

    71

    1453

  • tonsil
    3

    57

    34

    84

  • trachea
    7

    144

    27

    207

  • uterus
    10

    215

    27

    133

  • reticulocytes"
    7

    146

    14

    79

  • t-lymphocytes
    15

    312

    18

    213

  • b-lymphocytes
    19

    402

    26

    539

  • neutrophils
    11

    233

    66

    447

  • macrophages
    29

    610

    57

    593

  • sperm
    22

    464

    35

    748

 

Evolution

Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
  • tableheader
    100

    100

    100
  • tableheader
    22.3

    38.7

    99
  • tableheader
    86.6

    87.5

    97
  • tableheader
    -

    -

    93.5
  • tableheader
    -

    -

    -
  • tableheader
    94.1

    96.9

    93.5
  • tableheader
    -

    -

    -
  • tableheader
    91.9

    94.7

    93
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    70.6

    76.3

    -
  • tableheader
    71.5

    82.1

    66
  • tableheader
    -

    -

    71
  • tableheader
    -

    -

    53
  • tableheader
    -

    -

    -
  • tableheader
    26.6

    43.2

    35
  • tableheader
    35.3

    52.8

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
  • tableheader
    -

    -

    -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
 

Regulation

Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
 

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Kinections GIF
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
 

Disease Linkage

General Disease Association:

Neurological disorders
Specific Diseases (Non-cancerous):

Panic disorder; Social phobia; Agoraphobia
Comments:
Infusion of ectopic CCK4 peptide has been shown to induce panic-like symptoms in both panic disorder affected patients and non-affected controls, indicating that abnormal expression or activity of the CCK4 protein may play a role in the pathology of panic disorder and other anxiety disorders. These experimentally-induced panic symptoms can be prevented in a dose-dependent manner by the administration of selective CCK4 antagonists. In addition, a C-to-T transition mutation was observed at position -36 in the GC box of the CCK4 promoter sequence in patients with panic disorder. This suggests that the disorder may be due to aberrant expression of CCK4 rather than mutation of the protein sequence. Furthermore, ligands of the TSPO protein have been demonstrated to have potent anxiolytic activity in humans, thus they are thought to be useful for the treatment of anxiety-related disorders, including panic disorder. TSPO is an 18 KDa protein located in the outer mitochondrial membrane that mediates mitochondrial cholesterol import and neurosteroid biosynthesis. These endogenous metabolites have been shown to be significantly reduced during panic attacks and other anxiety-related events. Stimulants of this protein were shown to counteract the effects of CCK4-mediated panic attacks in an experimental context, indicating a link between CCK4 activity and neurosteroid levels in anxiety disorders. In animal studies, mice with mutated CCK4 protein display disrupted neural tube closure and abnormal stereociliary bundle orientation, indicating a role for the protein in neurodevelopment. Additionally, CCK4 protein is dynamically localized during the establishment of hair-cell polarity and appears to be a critical vertebrate regulator of planar cell polarity during development. Therefore, abnormal expression of CCK4 appears to be a contributing factor to the development of anxiety disorders (e.g. panic disorder), potentially through an interaction with neurosteroids or efffect on neurodevelopment. Panic disorder is a form of anxiety disorder characterized by panic attacks, which are sudden onset feelings of terror in non-dangerous situations. Social phobia is a phobic disorder characterized by a fear of specific public or social situations, interations with other people, or being evaluated/scrutinized. Agoraphobia is a phobic disorder characterized by the specific fear of being in a place/situation from which escape is difficult or embarrassing.
 
Gene Expression in Cancers:

The COSMIC website notes an up-regulated expression score for CCK4 in diverse human cancers of 606, which is 1.3-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 20 for this protein kinase in human cancers was 0.3-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:

Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.06 % in 25658 diverse cancer specimens. This rate is only -18 % lower than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 0.34 % in 854 skin cancers tested; 0.32 % in 1243 large intestine cancers tested; 0.17 % in 589 stomach cancers tested; 0.12 % in 1941 lung cancers tested.
Frequency of Mutated Sites:

None > 6 in 20,941 cancer specimens
Comments:
Only 3 deletions, 4 insertions or 1 complex mutation are noted on the COSMIC website.
 
COSMIC Entry:
PTK7
OMIM Entry:
601890
  • Home
  • Top of Page
Copyright 2019 Kinexus BioInformatics Corporation